These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Astemizole: an old anti-histamine as a new promising anti-cancer drug. García-Quiroz J; Camacho J Anticancer Agents Med Chem; 2011 Mar; 11(3):307-14. PubMed ID: 21443504 [TBL] [Abstract][Full Text] [Related]
5. Eag and HERG potassium channels as novel therapeutic targets in cancer. Asher V; Sowter H; Shaw R; Bali A; Khan R World J Surg Oncol; 2010 Dec; 8():113. PubMed ID: 21190577 [TBL] [Abstract][Full Text] [Related]
6. Role of voltage-gated potassium channels in cancer. Pardo LA; Contreras-Jurado C; Zientkowska M; Alves F; Stühmer W J Membr Biol; 2005 Jun; 205(3):115-24. PubMed ID: 16362499 [TBL] [Abstract][Full Text] [Related]
7. Eag1 K Han B; Tokay T; Zhang G; Sun P; Hou S Oxid Med Cell Longev; 2017; 2017():7371010. PubMed ID: 28367272 [No Abstract] [Full Text] [Related]
8. Overcoming challenges of HERG potassium channel liability through rational design: Eag1 inhibitors for cancer treatment. Toplak Ž; Hendrickx LA; Abdelaziz R; Shi X; Peigneur S; Tomašič T; Tytgat J; Peterlin-Mašič L; Pardo LA Med Res Rev; 2022 Jan; 42(1):183-226. PubMed ID: 33945158 [TBL] [Abstract][Full Text] [Related]
9. In vivo dual targeting of the oncogenic Ether-à-go-go-1 potassium channel by calcitriol and astemizole results in enhanced antineoplastic effects in breast tumors. García-Quiroz J; García-Becerra R; Santos-Martínez N; Barrera D; Ordaz-Rosado D; Avila E; Halhali A; Villanueva O; Ibarra-Sánchez MJ; Esparza-López J; Gamboa-Domínguez A; Camacho J; Larrea F; Díaz L BMC Cancer; 2014 Oct; 14():745. PubMed ID: 25280486 [TBL] [Abstract][Full Text] [Related]
10. Ether-à-go-go K Bauer CK; Schwarz JR J Physiol; 2018 Mar; 596(5):769-783. PubMed ID: 29333676 [TBL] [Abstract][Full Text] [Related]
12. Eag1: an emerging oncological target. Pardo LA; Stühmer W Cancer Res; 2008 Mar; 68(6):1611-3. PubMed ID: 18339837 [TBL] [Abstract][Full Text] [Related]
13. Identifying regulators for EAG1 channels with a novel electrophysiology and tryptophan fluorescence based screen. Brelidze TI; Carlson AE; Davies DR; Stewart LJ; Zagotta WN PLoS One; 2010 Sep; 5(9):. PubMed ID: 20824064 [TBL] [Abstract][Full Text] [Related]
14. Inducing Polyclonal Eag1-Specific Antibodies by Vaccination with a Linear Epitope Immunogen and Its Relation to Breast Tumorigenesis. Li Z; Zhu K; Gong X; Vasilescu S; Sun Y; Hong K; Li H; Li L; Shan Y Pathol Oncol Res; 2017 Oct; 23(4):761-767. PubMed ID: 28070819 [TBL] [Abstract][Full Text] [Related]
15. Ether à go-go potassium channel expression in soft tissue sarcoma patients. Mello de Queiroz F; Suarez-Kurtz G; Stühmer W; Pardo LA Mol Cancer; 2006 Oct; 5():42. PubMed ID: 17022811 [TBL] [Abstract][Full Text] [Related]
16. Aberrant expression of ether à go-go potassium channel in colorectal cancer patients and cell lines. Ding XW; Yan JJ; An P; Lü P; Luo HS World J Gastroenterol; 2007 Feb; 13(8):1257-61. PubMed ID: 17451210 [TBL] [Abstract][Full Text] [Related]
17. Potassium channels as tumour markers. Stühmer W; Alves F; Hartung F; Zientkowska M; Pardo LA FEBS Lett; 2006 May; 580(12):2850-2. PubMed ID: 16783874 [TBL] [Abstract][Full Text] [Related]
18. Antiproliferative and proapoptotic effects of astemizole on cervical cancer cells. de Guadalupe Chávez-López M; Hernández-Gallegos E; Vázquez-Sánchez AY; Gariglio P; Camacho J Int J Gynecol Cancer; 2014 Jun; 24(5):824-8. PubMed ID: 24819656 [TBL] [Abstract][Full Text] [Related]